Alzamend Neuro Number Of Employees vs. Working Capital
| ALZN Stock | USD 1.01 0.03 3.06% |
For Alzamend Neuro profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Alzamend Neuro to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Alzamend Neuro utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Alzamend Neuro's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Alzamend Neuro over time as well as its relative position and ranking within its peers.
Alzamend |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Alzamend Neuro Working Capital vs. Number Of Employees Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Alzamend Neuro's current stock value. Our valuation model uses many indicators to compare Alzamend Neuro value to that of its competitors to determine the firm's financial worth. Alzamend Neuro is rated below average in number of employees category among its peers. It also is rated below average in working capital category among its peers . At this time, Alzamend Neuro's Working Capital is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alzamend Neuro's earnings, one of the primary drivers of an investment's value.Alzamend Number Of Employees vs. Competition
Alzamend Neuro is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,518. Alzamend Neuro adds roughly 4.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Alzamend Working Capital vs. Number Of Employees
Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Alzamend Neuro |
| = | 4 |
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Alzamend Neuro |
| = | (2.77 M) |
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Alzamend Working Capital Comparison
Alzamend Neuro is currently under evaluation in working capital category among its peers.
Alzamend Neuro Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Alzamend Neuro, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Alzamend Neuro will eventually generate negative long term returns. The profitability progress is the general direction of Alzamend Neuro's change in net profit over the period of time. It can combine multiple indicators of Alzamend Neuro, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Loss | -13.4 M | -12.7 M | |
| Net Interest Income | -9.1 K | -9.5 K | |
| Operating Income | -8.9 M | -9.4 M | |
| Net Loss | -9 M | -9.4 M | |
| Income Before Tax | -9 M | -9.4 M | |
| Total Other Income Expense Net | -9.1 K | -8.6 K | |
| Net Loss | -9 M | -9.4 M | |
| Income Tax Expense | -166.6 K | -158.2 K | |
| Non Operating Income Net Other | 3.6 K | 3.4 K | |
| Change To Netincome | 4.1 M | 2.5 M | |
| Net Loss | (16.92) | (17.77) | |
| Income Quality | 0.96 | 0.81 | |
| Net Income Per E B T | 0.90 | 0.81 |
Alzamend Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Alzamend Neuro. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Alzamend Neuro position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Alzamend Neuro's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Alzamend Neuro without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
| All Next | Launch Module |
Use Investing Themes to Complement your Alzamend Neuro position
In addition to having Alzamend Neuro in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Services Thematic Idea Now
Services
Companies involved in delivering services to business or consumers across different industries and sectors. The Services theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Services Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
To fully project Alzamend Neuro's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Alzamend Neuro at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Alzamend Neuro's income statement, its balance sheet, and the statement of cash flows.